Research ArticleArticle
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo, Gary E. Myerson, Roy M. Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu, Randall M. Stevens and Airi Poder
The Journal of Rheumatology July 2016, jrheum.151376; DOI: https://doi.org/10.3899/jrheum.151376
Maurizio Cutolo
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Gary E. Myerson
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Roy M. Fleischmann
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Frédéric Lioté
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Federico Díaz-González
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Filip Van den Bosch
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Helena Marzo-Ortega
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Eugen Feist
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Kamal Shah
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
ChiaChi Hu
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Randall M. Stevens
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Airi Poder
From the Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Genoa, Italy; Arthritis and Rheumatology of Georgia, Atlanta, Georgia; Metroplex Clinical Research Center, Dallas, Texas, USA; AP-HP, Hôpital Lariboisière, Rheumatology Department, Université Paris Diderot, Paris, France; University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain; UZ Gent, Ghent, Belgium; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Charité – Universitätsmedizin Berlin, Department for Rheumatology and Clinical Immunology, Berlin, Germany; Celgene Corp., Summit, New Jersey, USA; Clinical Research Centre Ltd., Tartu, Estonia. Study sponsored by Celgene Corp. Editorial support for this article funded by Celgene. The authors are fully responsible for all content and editorial decisions. M. Cutolo has received research grants and/or consulting fees from Actelion, Bristol-Myers Squibb, Mundipharm, and Sanofi-Aventis. G.E. Myerson has received research grants and/or consulting fees from AbbVie, Actelion, Amgen, Bioventus, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Pfizer, Primus, Roche (Genentech), Takeda, and UCB. These authors have received research grants and/or consulting fees from Celgene Corp.: R.M. Fleischmann, F. Lioté, F. Díaz-González, and F. Van den Bosch. E. Feist has received research grants and/or consulting fees from Bristol-Myers Squibb, Eli Lilly, and Novartis. K. Shah and C. Hu are employees of Celgene Corp. R.M. Stevens is a former employee of Celgene Corp. M. Cutolo, MD, University of Genoa; G.E. Myerson, MD, Arthritis and Rheumatology of Georgia; R.M. Fleischmann, MD, Metroplex Clinical Research Center; F. Lioté, MD, AP-HP, Hôpital Lariboisière, Université Paris Diderot; F. Diaz-González, MD, University of La Laguna, Hospital Universitario de Canarias; F. Van den Bosch, MD, UZ Gent; H. Marzo-Ortega, MD, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; E. Feist, MD, Charité – Universitätsmedizin Berlin; K. Shah, MD, Celgene Corp.; C. Hu, EdM, MS, Celgene Corp.; R.M. Stevens, MD, Celgene Corp.; A. Poder, MD, Clinical Research Centre Ltd. Address correspondence to Dr. M. Cutolo, Research Laboratory and Division of Clinical Rheumatology, University of Genoa, Viale Benedetto XV, 6 16136 Genoa, Italy. E-mail: mcutolo@unige.it. Accepted for publication May 31, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo, Gary E. Myerson, Roy M. Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu, Randall M. Stevens, Airi Poder
The Journal of Rheumatology Jul 2016, jrheum.151376; DOI: 10.3899/jrheum.151376
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo, Gary E. Myerson, Roy M. Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu, Randall M. Stevens, Airi Poder
The Journal of Rheumatology Jul 2016, jrheum.151376; DOI: 10.3899/jrheum.151376